|Ms. Alex K. Blankenship||CEO, Pres, Sec., Treasurer, Principal Exec. Ofc., Principal Fin. & Acc. Ofc. and Director||50.5k||N/A||1963|
AngioSoma, Inc. operates as a clinical stage biotechnology company. The company's lead drug candidates include Liprostin that completed Phase I and three Phase II clinical trials, and Prostaglandin E1 that completed Phase II clinical trials for the treatment of peripheral artery diseases. It also markets a line of nutraceutical supplements under the SomaCeuticals name. AngioSoma, Inc. was founded in 2016 and is based in Houston, Texas.
AngioSoma, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.